Severe asthma remains a complex disease shaped not only by airway inflammation, but by real‑world clinical, lifestyle, and patient factors that influence long‑term treatment decisions. At ATS 2026, join GSK Medical Affairs for two on‑site educational experiences that explore how evolving evidence and meaningful patient‑centered dialogue can inform more intentional severe asthma care.
Beyond the Airway: Conversations That Shape Severe Asthma Treatment Decisions
Sunday, May 17, 2026 | 1:00–1:45 P.M.
Innovation Theater 4
This interactive symposium brings clinician–patient perspectives to the forefront through live dialogue focused on real‑world decision‑making in severe asthma. Despite therapeutic advances, treatment choices are often shaped by individualized factors such as disease complexity, treatment burden, lifestyle considerations, and patient preferences.
Led by Njira L. Lugogo, MD, MS and Diego J. Maselli, MD, FCCP, ATSF, the session highlights shared decision‑making as a practical, patient‑centered framework for aligning clinical goals with what matters most to patients. The discussion will also explore how health disparities and social determinants may influence care pathways, offering practical insights to support sustained asthma management through collaborative treatment conversations.
Behind the Science: Ultra Long‑Acting Approach to Severe Asthma — Two Year Evidence
Monday, May 18, 2026 | 12:35–12:55 P.M.
Innovation Hub 3
This Innovation Hub presentation provides a focused review of two‑year clinical findings evaluating an ultra long‑acting therapeutic approach for patients with severe asthma characterized by an eosinophilic phenotype. Presented by Dr. Michael Wechsler, the session will highlight evidence demonstrating sustained suppression of Type 2 inflammation, reductions in exacerbations, and a consistent long‑term safety profile with no new safety concerns identified.
The discussion will also examine how durable, well‑tolerated treatment strategies may support optimization of asthma management prior to escalation to high‑dose corticosteroids, offering a clinically relevant perspective on long‑term disease control.
These programs were developed by GSK and are neither sponsored by nor endorsed by ATS and do not offer CME/CE credit.
Visit the GSK Medical Affairs booth to continue the conversation and explore additional scientific resources available throughout the meeting.